25 XP   0   0   10

Kalbe Farma Tbk PT
Buy, Hold or Sell?

Let's analyse Kalbe together

PenkeI guess you are interested in Kalbe Farma Tbk PT. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Kalbe Farma Tbk PT. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Kalbe Farma Tbk PT

I send you an email if I find something interesting about Kalbe Farma Tbk PT.

Quick analysis of Kalbe (30 sec.)










What can you expect buying and holding a share of Kalbe? (30 sec.)

How much money do you get?

How much money do you get?
Rp0.02
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
Rp499.83
Expected worth in 1 year
Rp736.33
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
Rp388.49
Return On Investment
27.6%

For what price can you sell your share?

Current Price per Share
Rp1,410.00
Expected price per share
Rp1,375 - Rp1,535
How sure are you?
50%

1. Valuation of Kalbe (5 min.)




Live pricePrice per Share (EOD)

Rp1,410.00

Intrinsic Value Per Share

Rp-146.81 - Rp450.91

Total Value Per Share

Rp353.02 - Rp950.74

2. Growth of Kalbe (5 min.)




Is Kalbe growing?

Current yearPrevious yearGrowGrow %
How rich?$2.3b$2b$273.4m11.8%

How much money is Kalbe making?

Current yearPrevious yearGrowGrow %
Making money$276.6m$338.2m-$61.5m-22.2%
Net Profit Margin9.1%11.7%--

How much money comes from the company's main activities?

3. Financial Health of Kalbe (5 min.)




What can you expect buying and holding a share of Kalbe? (5 min.)

Welcome investor! Kalbe's management wants to use your money to grow the business. In return you get a share of Kalbe.

What can you expect buying and holding a share of Kalbe?

First you should know what it really means to hold a share of Kalbe. And how you can make/lose money.

Speculation

The Price per Share of Kalbe is Rp1,410. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kalbe.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kalbe, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is Rp499.83. Based on the TTM, the Book Value Change Per Share is Rp59.12 per quarter. Based on the YOY, the Book Value Change Per Share is Rp22.99 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is Rp38.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kalbe.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 Rp% of Price per ShareRp% of Price per ShareRp% of Price per ShareRp% of Price per ShareRp% of Price per Share
Usd Eps0.010.0%0.010.0%0.010.0%0.010.0%0.010.0%
Usd Book Value Change Per Share0.010.0%0.010.0%0.000.0%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.010.0%0.010.0%0.010.0%0.010.0%0.010.0%
Usd Price Per Share0.16-0.16-0.21-0.17-0.16-
Price to Earnings Ratio26.92-26.92-28.58-26.99-29.92-
Price-to-Total Gains Ratio16.58-16.58-35.14-27.69-30.39-
Price to Book Ratio3.22-3.22-4.74-4.07-5.09-
Price-to-Total Gains Ratio16.58-16.58-35.14-27.69-30.39-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.141
Number of shares7092
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.00
Usd Total Gains Per Share0.010.01
Gains per Quarter (7092 shares)68.8846.53
Gains per Year (7092 shares)275.52186.11
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
11081682668898176
2216335542175197362
3323503818263295548
44316711094351394734
55398391370438492920
6647100616465265911106
7755117419226146891292
8862134221987017881478
9970150924747898861664
101078167727508769851850

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%23.00.01.095.8%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%24.00.00.0100.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%23.00.01.095.8%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%24.00.00.0100.0%

Fundamentals of Kalbe

About Kalbe Farma Tbk PT

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals; Consumer Health; Nutritionals and Distribution; and Logistic. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business; and E-health products. It operates Mitrasana Clinics, a health care service. In addition, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.

Fundamental data was last updated by Penke on 2024-04-22 16:48:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Kalbe Farma Tbk PT.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Kalbe earns for each Rp1 of revenue.

  • Above 10% is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 9.1% means that Rp0.09 for each Rp1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kalbe Farma Tbk PT:

  • The MRQ is 9.1%. The company is making a profit. +1
  • The TTM is 9.1%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ9.1%TTM9.1%0.0%
TTM9.1%YOY11.7%-2.6%
TTM9.1%5Y11.2%-2.1%
5Y11.2%10Y11.4%-0.3%
1.1.2. Return on Assets

Shows how efficient Kalbe is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • 10.2% Return on Assets means that Kalbe generated Rp0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kalbe Farma Tbk PT:

  • The MRQ is 10.2%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 10.2%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ10.2%TTM10.2%0.0%
TTM10.2%YOY12.4%-2.2%
TTM10.2%5Y11.9%-1.7%
5Y11.9%10Y13.4%-1.5%
1.1.3. Return on Equity

Shows how efficient Kalbe is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • 12.9% Return on Equity means Kalbe generated Rp0.13 for each Rp1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kalbe Farma Tbk PT:

  • The MRQ is 12.9%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 12.9%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ12.9%TTM12.9%0.0%
TTM12.9%YOY16.6%-3.7%
TTM12.9%5Y15.4%-2.5%
5Y15.4%10Y17.3%-1.8%

1.2. Operating Efficiency of Kalbe Farma Tbk PT.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Kalbe is operating .

  • Measures how much profit Kalbe makes for each Rp1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 0.0% means the company generated Rp0.00  for each Rp1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kalbe Farma Tbk PT:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY14.7%-14.7%
TTM-5Y12.1%-12.1%
5Y12.1%10Y12.3%-0.2%
1.2.2. Operating Ratio

Measures how efficient Kalbe is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 1.49 means that the operating costs are Rp1.49 for each Rp1 in net sales.

Let's take a look of the Operating Ratio trends of Kalbe Farma Tbk PT:

  • The MRQ is 1.493. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.493. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.493TTM1.4930.000
TTM1.493YOY1.459+0.034
TTM1.4935Y1.438+0.054
5Y1.43810Y1.316+0.122

1.3. Liquidity of Kalbe Farma Tbk PT.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Kalbe is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 4.91 means the company has Rp4.91 in assets for each Rp1 in short-term debts.

Let's take a look of the Current Ratio trends of Kalbe Farma Tbk PT:

  • The MRQ is 4.908. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.908. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.908TTM4.9080.000
TTM4.908YOY3.771+1.137
TTM4.9085Y4.319+0.589
5Y4.31910Y3.859+0.460
1.3.2. Quick Ratio

Measures if Kalbe is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 1.49 means the company can pay off Rp1.49 for each Rp1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kalbe Farma Tbk PT:

  • The MRQ is 1.485. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.485. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.485TTM1.4850.000
TTM1.485YOY1.998-0.513
TTM1.4855Y2.396-0.910
5Y2.39610Y2.371+0.024

1.4. Solvency of Kalbe Farma Tbk PT.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Kalbe assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kalbe to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.15 means that Kalbe assets are financed with 14.6% credit (debt) and the remaining percentage (100% - 14.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kalbe Farma Tbk PT:

  • The MRQ is 0.146. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.146. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.146TTM0.1460.000
TTM0.146YOY0.252-0.106
TTM0.1465Y0.208-0.062
5Y0.20810Y0.199+0.009
1.4.2. Debt to Equity Ratio

Measures if Kalbe is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 18.4% means that company has Rp0.18 debt for each Rp1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kalbe Farma Tbk PT:

  • The MRQ is 0.184. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.184. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.184TTM0.1840.000
TTM0.184YOY0.336-0.152
TTM0.1845Y0.270-0.086
5Y0.27010Y0.257+0.013

2. Market Valuation of Kalbe Farma Tbk PT

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every Rp1 in earnings Kalbe generates.

  • Above 15 is considered overpriced but always compare Kalbe to the Drug Manufacturers - General industry mean.
  • A PE ratio of 26.92 means the investor is paying Rp26.92 for every Rp1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kalbe Farma Tbk PT:

  • The EOD is 23.573. Based on the earnings, the company is fair priced.
  • The MRQ is 26.917. Based on the earnings, the company is overpriced. -1
  • The TTM is 26.917. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD23.573MRQ26.917-3.344
MRQ26.917TTM26.9170.000
TTM26.917YOY28.583-1.667
TTM26.9175Y26.990-0.074
5Y26.99010Y29.925-2.935
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kalbe Farma Tbk PT:

  • The EOD is 37.732. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 43.084. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 43.084. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD37.732MRQ43.084-5.352
MRQ43.084TTM43.0840.000
TTM43.084YOY240.610-197.525
TTM43.0845Y98.710-55.625
5Y98.71010Y80.446+18.264
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Kalbe is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 3.22 means the investor is paying Rp3.22 for each Rp1 in book value.

Let's take a look of the Price to Book Ratio trends of Kalbe Farma Tbk PT:

  • The EOD is 2.821. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.221. Based on the equity, the company is fair priced.
  • The TTM is 3.221. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.821MRQ3.221-0.400
MRQ3.221TTM3.2210.000
TTM3.221YOY4.742-1.521
TTM3.2215Y4.072-0.851
5Y4.07210Y5.088-1.015
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Kalbe Farma Tbk PT compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--59.12459.1240%22.993+157%34.710+70%31.607+87%
Book Value Per Share--499.831499.8310%440.708+13%417.195+20%341.305+46%
Current Ratio--4.9084.9080%3.771+30%4.319+14%3.859+27%
Debt To Asset Ratio--0.1460.1460%0.252-42%0.208-30%0.199-27%
Debt To Equity Ratio--0.1840.1840%0.336-45%0.270-32%0.257-28%
Dividend Per Share--38.00038.0000%36.486+4%30.897+23%25.697+48%
Eps--59.81459.8140%73.120-18%62.529-4%55.337+8%
Free Cash Flow Per Share--37.36837.3680%8.686+330%32.459+15%29.936+25%
Free Cash Flow To Equity Per Share--37.36837.3680%-43.324+216%11.169+235%10.906+243%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--450.907--------
Intrinsic Value_10Y_min---146.807--------
Intrinsic Value_1Y_max--35.281--------
Intrinsic Value_1Y_min--17.658--------
Intrinsic Value_3Y_max--113.553--------
Intrinsic Value_3Y_min--25.334--------
Intrinsic Value_5Y_max--200.925--------
Intrinsic Value_5Y_min--2.569--------
Market Cap65220395458560.000-14%74471582670100.00074471582670100.0000%96674290546900.000-23%78431068468130.000-5%75934543310080.000-2%
Net Profit Margin--0.0910.0910%0.117-22%0.112-19%0.114-21%
Operating Margin----0%0.147-100%0.121-100%0.123-100%
Operating Ratio--1.4931.4930%1.459+2%1.438+4%1.316+13%
Pb Ratio2.821-14%3.2213.2210%4.742-32%4.072-21%5.088-37%
Pe Ratio23.573-14%26.91726.9170%28.583-6%26.9900%29.925-10%
Price Per Share1410.000-14%1610.0001610.0000%2090.000-23%1683.000-4%1629.000-1%
Price To Free Cash Flow Ratio37.732-14%43.08443.0840%240.610-82%98.710-56%80.446-46%
Price To Total Gains Ratio14.518-14%16.57716.5770%35.139-53%27.689-40%30.389-45%
Quick Ratio--1.4851.4850%1.998-26%2.396-38%2.371-37%
Return On Assets--0.1020.1020%0.124-18%0.119-14%0.134-24%
Return On Equity--0.1290.1290%0.166-22%0.154-16%0.173-25%
Total Gains Per Share--97.12497.1240%59.479+63%65.607+48%57.304+69%
Usd Book Value--2312002201.0222312002201.0220%2038521797.151+13%1943917632.595+19%1591309539.928+45%
Usd Book Value Change Per Share--0.0060.0060%0.002+157%0.003+70%0.003+87%
Usd Book Value Per Share--0.0500.0500%0.044+13%0.042+20%0.034+46%
Usd Dividend Per Share--0.0040.0040%0.004+4%0.003+23%0.003+48%
Usd Eps--0.0060.0060%0.007-18%0.006-4%0.006+8%
Usd Free Cash Flow--172850295.580172850295.5800%40178886.609+330%151575133.870+14%139622142.799+24%
Usd Free Cash Flow Per Share--0.0040.0040%0.001+330%0.003+15%0.003+25%
Usd Free Cash Flow To Equity Per Share--0.0040.0040%-0.004+216%0.001+235%0.001+243%
Usd Market Cap6522039545.856-14%7447158267.0107447158267.0100%9667429054.690-23%7843106846.813-5%7593454331.008-2%
Usd Price Per Share0.141-14%0.1610.1610%0.209-23%0.168-4%0.163-1%
Usd Profit--276674804.006276674804.0060%338220976.902-18%291452071.116-5%258019967.391+7%
Usd Revenue--3044913407.7623044913407.7620%2893350264.672+5%2627799251.778+16%2272766166.704+34%
Usd Total Gains Per Share--0.0100.0100%0.006+63%0.007+48%0.006+69%
 EOD+4 -4MRQTTM+0 -0YOY+22 -135Y+22 -1310Y+25 -10

3.2. Fundamental Score

Let's check the fundamental score of Kalbe Farma Tbk PT based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1523.573
Price to Book Ratio (EOD)Between0-12.821
Net Profit Margin (MRQ)Greater than00.091
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.485
Current Ratio (MRQ)Greater than14.908
Debt to Asset Ratio (MRQ)Less than10.146
Debt to Equity Ratio (MRQ)Less than10.184
Return on Equity (MRQ)Greater than0.150.129
Return on Assets (MRQ)Greater than0.050.102
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Kalbe Farma Tbk PT based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.067
Ma 20Greater thanMa 501,457.000
Ma 50Greater thanMa 1001,469.300
Ma 100Greater thanMa 2001,535.650
OpenGreater thanClose1,450.000
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Net Interest Income  106,882,872-31,160,47175,722,401-22,314,64153,407,759-26,639,71726,768,042-33,654,289-6,886,246



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in IDR. All numbers in thousands.

Summary
Total Assets27,057,568,182
Total Liabilities3,937,546,172
Total Stockholder Equity21,418,856,503
 As reported
Total Liabilities 3,937,546,172
Total Stockholder Equity+ 21,418,856,503
Total Assets = 27,057,568,182

Assets

Total Assets27,057,568,182
Total Current Assets15,917,724,101
Long-term Assets11,139,844,081
Total Current Assets
Cash And Cash Equivalents 3,232,420,597
Short-term Investments 165,496,270
Net Receivables 4,651,970,696
Inventory 6,791,979,793
Other Current Assets 99,495,741
Total Current Assets  (as reported)15,917,724,101
Total Current Assets  (calculated)14,941,363,097
+/- 976,361,004
Long-term Assets
Property Plant Equipment 8,537,934,710
Goodwill 479,347,420
Intangible Assets 1,327,234,155
Long-term Assets Other 20,861,248
Long-term Assets  (as reported)11,139,844,081
Long-term Assets  (calculated)10,365,377,532
+/- 774,466,550

Liabilities & Shareholders' Equity

Total Current Liabilities3,243,168,545
Long-term Liabilities694,377,627
Total Stockholder Equity21,418,856,503
Total Current Liabilities
Short Long Term Debt 278,293,959
Accounts payable 1,690,719,606
Total Current Liabilities  (as reported)3,243,168,545
Total Current Liabilities  (calculated)1,969,013,565
+/- 1,274,154,980
Long-term Liabilities
Long term Debt 298,336,872
Capital Lease Obligations Min Short Term Debt41,907,520
Long-term Liabilities  (as reported)694,377,627
Long-term Liabilities  (calculated)340,244,392
+/- 354,133,235
Total Stockholder Equity
Retained Earnings 21,162,752,456
Total Stockholder Equity (as reported)21,418,856,503
Total Stockholder Equity (calculated)21,162,752,456
+/- 256,104,047
Other
Capital Stock468,751,221
Common Stock Shares Outstanding 46,255,641
Net Invested Capital 21,995,487,335
Net Working Capital 12,674,555,556
Property Plant and Equipment Gross 14,283,621,974



Balance Sheet

Currency in IDR. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311996-12-311995-12-311994-12-31
> Total Assets 
0
0
0
1,757,841,000
1,877,316,000
2,015,537,544
2,448,390,203
3,016,864,059
4,727,929,160
4,624,619,204
5,138,212,507
5,703,832,412
6,482,446,670
7,032,496,663
8,274,554,113
9,417,957,181
11,315,061,275
12,425,032,368
13,696,417,381
15,226,009,211
16,616,239,416
18,146,206,145
20,264,726,863
22,564,300,317
25,666,635,156
27,241,313,026
27,057,568,182
27,057,568,18227,241,313,02625,666,635,15622,564,300,31720,264,726,86318,146,206,14516,616,239,41615,226,009,21113,696,417,38112,425,032,36811,315,061,2759,417,957,1818,274,554,1137,032,496,6636,482,446,6705,703,832,4125,138,212,5074,624,619,2044,727,929,1603,016,864,0592,448,390,2032,015,537,5441,877,316,0001,757,841,000000
   > Total Current Assets 
642,498,522
777,803,875
788,624,853
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,748,491,609
9,572,529,768
10,042,738,650
10,648,288,387
11,222,490,978
13,075,331,881
15,712,209,508
16,710,229,570
15,917,724,101
15,917,724,10116,710,229,57015,712,209,50813,075,331,88111,222,490,97810,648,288,38710,042,738,6509,572,529,7688,748,491,609000000000000000788,624,853777,803,875642,498,522
       Cash And Cash Equivalents 
0
0
0
129,536,000
246,891,000
212,576,254
206,343,458
143,852,546
228,155,979
1,261,454,016
0
1,321,797,625
0
1,901,871,765
2,291,335,810
1,859,662,706
0
1,894,609,528
2,066,322,846
2,895,582,003
2,784,705,831
3,153,327,557
3,040,487,104
2,883,075,063
3,323,690,210
1,634,556,836
3,232,420,597
3,232,420,5971,634,556,8363,323,690,2102,883,075,0633,040,487,1043,153,327,5572,784,705,8312,895,582,0032,066,322,8461,894,609,52801,859,662,7062,291,335,8101,901,871,76501,321,797,62501,261,454,016228,155,979143,852,546206,343,458212,576,254246,891,000129,536,000000
       Short-term Investments 
0
0
0
120,314,000
26,385,000
299,974,154
742,666,760
1,103,262,174
1,572,739,598
259,701,412
0
124,748,589
0
5,315,920
113,871,418
239,187,296
0
199,389,673
155,753,503
179,326,121
186,495,243
178,719,216
195,618,536
188,316,348
258,923,290
145,306,837
165,496,270
165,496,270145,306,837258,923,290188,316,348195,618,536178,719,216186,495,243179,326,121155,753,503199,389,6730239,187,296113,871,4185,315,9200124,748,5890259,701,4121,572,739,5981,103,262,174742,666,760299,974,15426,385,000120,314,000000
       Net Receivables 
124,924,176
202,543,236
204,814,580
364,153,000
423,918,000
466,558,873
547,151,424
616,858,629
632,313,904
798,032,428
943,160,674
1,013,681,172
1,326,418,432
1,375,072,810
1,635,311,256
1,938,155,600
2,273,378,789
2,464,901,529
2,354,779,772
2,725,807,581
2,967,693,268
3,373,569,270
3,697,660,122
3,477,220,763
3,431,018,099
4,613,623,001
4,651,970,696
4,651,970,6964,613,623,0013,431,018,0993,477,220,7633,697,660,1223,373,569,2702,967,693,2682,725,807,5812,354,779,7722,464,901,5292,273,378,7891,938,155,6001,635,311,2561,375,072,8101,326,418,4321,013,681,172943,160,674798,032,428632,313,904616,858,629547,151,424466,558,873423,918,000364,153,000204,814,580202,543,236124,924,176
       Inventory 
85,300,596
98,854,311
78,360,387
275,463,000
340,475,000
330,207,706
305,613,925
446,229,262
1,093,722,204
884,654,354
1,427,067,985
1,606,123,882
1,561,382,419
1,550,828,820
1,705,189,186
2,115,483,767
3,053,494,514
3,090,544,151
3,003,149,536
3,344,404,151
3,557,496,638
3,602,941,730
3,885,097,804
3,745,067,401
5,162,582,563
7,138,818,071
6,791,979,793
6,791,979,7937,138,818,0715,162,582,5633,745,067,4013,885,097,8043,602,941,7303,557,496,6383,344,404,1513,003,149,5363,090,544,1513,053,494,5142,115,483,7671,705,189,1861,550,828,8201,561,382,4191,606,123,8821,427,067,985884,654,3541,093,722,204446,229,262305,613,925330,207,706340,475,000275,463,00078,360,38798,854,31185,300,596
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,653,479,443
6,572,288,916
7,497,917,759
9,042,235,884
9,488,968,437
9,954,425,649
10,531,083,456
11,139,844,081
11,139,844,08110,531,083,4569,954,425,6499,488,968,4379,042,235,8847,497,917,7596,572,288,9165,653,479,4430000000000000000000
       Property Plant Equipment 
135,843,984
151,023,963
175,029,461
404,428,000
444,305,000
493,813,551
520,374,422
557,746,593
859,117,129
815,420,687
983,020,082
1,097,030,469
1,398,127,877
1,605,266,031
1,860,288,484
2,254,763,273
2,925,546,783
3,404,457,131
3,938,494,051
4,555,756,102
5,342,659,713
6,252,801,150
7,977,898,516
8,469,091,572
8,301,982,806
8,346,611,361
8,537,934,710
8,537,934,7108,346,611,3618,301,982,8068,469,091,5727,977,898,5166,252,801,1505,342,659,7134,555,756,1023,938,494,0513,404,457,1312,925,546,7832,254,763,2731,860,288,4841,605,266,0311,398,127,8771,097,030,469983,020,082815,420,687859,117,129557,746,593520,374,422493,813,551444,305,000404,428,000175,029,461151,023,963135,843,984
       Goodwill 
0
0
0
44,085,000
44,086,000
37,712,015
34,540,865
30,730,804
36,121,365
32,092,703
0
24,264,604
210,683,228
195,217,373
195,217,373
298,588,100
294,015,103
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
293,279,778
195,225,854
209,683,528
479,347,420
479,347,420
479,347,420479,347,420209,683,528195,225,854293,279,778293,279,778293,279,778293,279,778293,279,778293,279,778294,015,103298,588,100195,217,373195,217,373210,683,22824,264,604032,092,70336,121,36530,730,80434,540,86537,712,01544,086,00044,085,000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
57,650,343
89,131,940
78,861,566
86,106,431
0
0
0
0
0
0000086,106,43178,861,56689,131,94057,650,343000000000000000000
       Intangible Assets 
0
0
0
76,629,000
71,529,000
66,419,301
61,330,215
55,602,217
63,615,572
270,589,943
292,150,844
312,723,407
261,359,311
237,557,876
233,007,451
341,173,421
385,267,577
421,707,972
121,999,977
106,926,537
126,293,051
171,022,168
399,173,412
464,791,872
923,047,655
1,026,046,475
1,327,234,155
1,327,234,1551,026,046,475923,047,655464,791,872399,173,412171,022,168126,293,051106,926,537121,999,977421,707,972385,267,577341,173,421233,007,451237,557,876261,359,311312,723,407292,150,844270,589,94363,615,57255,602,21761,330,21566,419,30171,529,00076,629,000000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
41,987,336
23,186,238
28,066,107
33,945,038
19,071,674
16,965,003
14,008,249
20,861,248
20,861,24814,008,24916,965,00319,071,67433,945,03828,066,10723,186,23841,987,3360000000000000000000
> Total Liabilities 
0
0
0
1,452,105,000
1,531,342,000
1,364,124,530
1,424,895,577
1,537,379,863
1,821,583,815
1,080,565,632
1,121,539,026
1,359,296,592
1,691,774,827
1,260,579,634
1,758,619,054
2,046,313,566
2,815,103,309
2,607,556,689
3,231,294,418
2,762,162,070
2,722,207,634
2,851,611,349
3,559,144,387
5,158,767,388
6,087,108,914
6,856,095,054
3,937,546,172
3,937,546,1726,856,095,0546,087,108,9145,158,767,3883,559,144,3872,851,611,3492,722,207,6342,762,162,0703,231,294,4182,607,556,6892,815,103,3092,046,313,5661,758,619,0541,260,579,6341,691,774,8271,359,296,5921,121,539,0261,080,565,6321,821,583,8151,537,379,8631,424,895,5771,364,124,5301,531,342,0001,452,105,000000
   > Total Current Liabilities 
293,146,778
253,736,914
193,867,231
433,074,000
500,475,000
1,133,666,099
1,161,321,161
782,589,561
903,515,824
658,759,611
754,629,114
1,250,371,831
1,574,137,416
1,146,489,094
1,630,588,529
1,891,617,854
2,640,590,024
2,385,920,172
2,365,880,491
2,317,161,787
2,227,336,012
2,286,167,472
2,577,108,806
3,176,226,388
3,534,656,089
4,431,038,460
3,243,168,545
3,243,168,5454,431,038,4603,534,656,0893,176,226,3882,577,108,8062,286,167,4722,227,336,0122,317,161,7872,365,880,4912,385,920,1722,640,590,0241,891,617,8541,630,588,5291,146,489,0941,574,137,4161,250,371,831754,629,114658,759,611903,515,824782,589,5611,161,321,1611,133,666,099500,475,000433,074,000193,867,231253,736,914293,146,778
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
266,148,059
147,394,441
171,441,295
96,257,226
169,062,533
220,500,000
0
705,600,000
0
0705,600,0000220,500,000169,062,53396,257,226171,441,295147,394,441266,148,059000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
147,394,441
171,441,295
96,257,226
169,062,533
344,343,143
69,999,978
829,302,294
278,293,959
278,293,959829,302,29469,999,978344,343,143169,062,53396,257,226171,441,295147,394,4410000000000000000000
       Accounts payable 
31,304,142
23,331,297
21,145,970
73,674,000
101,289,000
99,391,211
103,118,924
151,360,549
306,454,180
344,374,324
328,290,780
305,567,570
481,511,454
488,240,634
850,398,382
808,864,742
1,151,654,580
1,133,092,820
1,068,665,524
1,127,307,240
1,108,551,385
1,289,897,769
1,215,860,422
1,240,385,598
1,667,595,791
1,996,614,608
1,690,719,606
1,690,719,6061,996,614,6081,667,595,7911,240,385,5981,215,860,4221,289,897,7691,108,551,3851,127,307,2401,068,665,5241,133,092,8201,151,654,580808,864,742850,398,382488,240,634481,511,454305,567,570328,290,780344,374,324306,454,180151,360,549103,118,92499,391,211101,289,00073,674,00021,145,97023,331,29731,304,142
       Other Current Liabilities 
29,373,535
17,548,365
32,410,687
140,540,000
177,033,000
219,295,972
284,156,726
354,990,788
426,334,849
276,072,721
380,185,929
539,791,313
752,993,595
633,649,816
639,848,211
878,206,920
905,020,144
1,000,918,251
529,770,463
601,568,161
599,028,509
560,236,764
684,107,305
1,034,408,066
1,038,436,604
961,791,105
0
0961,791,1051,038,436,6041,034,408,066684,107,305560,236,764599,028,509601,568,161529,770,4631,000,918,251905,020,144878,206,920639,848,211633,649,816752,993,595539,791,313380,185,929276,072,721426,334,849354,990,788284,156,726219,295,972177,033,000140,540,00032,410,68717,548,36529,373,535
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
445,000,282
494,871,622
565,443,877
982,035,581
1,111,491,962
866,101,274
712,946,364
694,377,627
694,377,627712,946,364866,101,2741,111,491,962982,035,581565,443,877494,871,622445,000,2820000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
130,932,925
134,416,976
145,602,994
260,001,844
647,688,345
788,551,546
532,509,477
311,898,813
0
0311,898,813532,509,477788,551,546647,688,345260,001,844145,602,994134,416,976130,932,925000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-266,148,059
-143,920,256
-168,229,181
-94,938,015
-168,927,151
-129,846,423
65,877,999
-654,215,433
41,907,520
41,907,520-654,215,43365,877,999-129,846,423-168,927,151-94,938,015-168,229,181-143,920,256-266,148,059000000000000000000
       Other Liabilities 
2,158,373
1,445,930
0
0
7,335,000
15,777,933
24,295,980
36,494,115
57,064,639
71,107,653
88,944,720
100,723,188
108,265,139
105,706,561
117,826,727
143,685,010
162,581,805
164,437,997
261,317,981
310,583,306
349,268,627
305,442,034
334,347,236
323,440,239
333,591,797
0
0
00333,591,797323,440,239334,347,236305,442,034349,268,627310,583,306261,317,981164,437,997162,581,805143,685,010117,826,727105,706,561108,265,139100,723,18888,944,72071,107,65357,064,63936,494,11524,295,98015,777,9337,335,000001,445,9302,158,373
> Total Stockholder Equity
0
0
0
188,494,000
220,774,000
489,918,227
828,957,856
1,219,193,365
2,389,006,142
2,994,816,752
3,386,861,941
3,622,399,153
4,310,437,877
5,373,784,301
6,214,818,131
7,054,054,237
8,108,241,522
9,382,023,164
10,465,122,964
11,909,264,708
13,280,807,475
14,623,457,976
15,893,126,391
17,405,532,929
19,579,526,243
20,385,217,972
21,418,856,503
21,418,856,50320,385,217,97219,579,526,24317,405,532,92915,893,126,39114,623,457,97613,280,807,47511,909,264,70810,465,122,9649,382,023,1648,108,241,5227,054,054,2376,214,818,1315,373,784,3014,310,437,8773,622,399,1533,386,861,9412,994,816,7522,389,006,1421,219,193,365828,957,856489,918,227220,774,000188,494,000000
   Retained Earnings 
95,280,838
142,186,854
190,454,329
0
0
62,029,194
374,122,812
735,107,585
1,876,587,744
2,497,335,415
3,101,988,938
3,717,529,710
4,529,299,395
5,581,253,811
6,407,439,271
7,250,740,056
7,633,188,371
8,900,997,960
10,006,397,635
11,415,504,887
12,787,858,134
14,073,109,114
15,361,120,511
16,875,670,701
18,746,849,491
20,497,738,765
21,162,752,456
21,162,752,45620,497,738,76518,746,849,49116,875,670,70115,361,120,51114,073,109,11412,787,858,13411,415,504,88710,006,397,6358,900,997,9607,633,188,3717,250,740,0566,407,439,2715,581,253,8114,529,299,3953,717,529,7103,101,988,9382,497,335,4151,876,587,744735,107,585374,122,81262,029,19400190,454,329142,186,85495,280,838
   Accumulated Other Comprehensive Income 000000000000000000000000000
   Capital Surplus 0-34,118,674-34,118,674-34,118,674-34,118,674-34,118,674-34,118,674-34,118,674-34,118,674000000000000000000
   Treasury Stock00-2,063,200-2,063,2000000000-687,283,369-687,283,369-688,603,393-688,603,393-569,510,784-218,311,3260000000000



Balance Sheet

Currency in IDR. All numbers in thousands.




Cash Flow

Currency in IDR. All numbers in thousands.




Income Statement

Currency in IDR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue30,449,134,078
Cost of Revenue-18,625,888,544
Gross Profit11,823,245,53311,823,245,533
 
Operating Income (+$)
Gross Profit11,823,245,533
Operating Expense-26,823,997,049
Operating Income3,625,137,029-15,000,751,515
 
Operating Expense (+$)
Research Development627,259,051
Selling General Administrative4,478,075,952
Selling And Marketing Expenses0
Operating Expense26,823,997,0495,105,335,003
 
Net Interest Income (+$)
Interest Income88,217,597
Interest Expense-82,958,207
Other Finance Cost-12,145,637
Net Interest Income-6,886,246
 
Pretax Income (+$)
Operating Income3,625,137,029
Net Interest Income-6,886,246
Other Non-Operating Income Expenses0
Income Before Tax (EBT)3,606,237,2043,625,137,029
EBIT - interestExpense = -82,958,207
2,766,748,040
2,849,706,247
Interest Expense82,958,207
Earnings Before Interest and Taxes (EBIT)03,689,195,411
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax3,606,237,204
Tax Provision-827,832,384
Net Income From Continuing Ops2,778,404,8202,778,404,820
Net Income2,766,748,040
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net06,886,246
 

Technical Analysis of Kalbe
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kalbe. The general trend of Kalbe is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kalbe's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kalbe Farma Tbk PT.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 1,435 < 1,525 < 1,535.

The bearish price targets are: 1,375.

Tweet this
Kalbe Farma Tbk PT Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kalbe Farma Tbk PT. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kalbe Farma Tbk PT Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kalbe Farma Tbk PT. The current macd is -16.98242732.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Kalbe price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Kalbe. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Kalbe price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Kalbe Farma Tbk PT Daily Moving Average Convergence/Divergence (MACD) ChartKalbe Farma Tbk PT Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kalbe Farma Tbk PT. The current adx is 17.99.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Kalbe shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Kalbe Farma Tbk PT Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kalbe Farma Tbk PT. The current sar is 1,497.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Kalbe Farma Tbk PT Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kalbe Farma Tbk PT. The current rsi is 42.07. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Kalbe Farma Tbk PT Daily Relative Strength Index (RSI) ChartKalbe Farma Tbk PT Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kalbe Farma Tbk PT. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Kalbe price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Kalbe Farma Tbk PT Daily Stochastic Oscillator ChartKalbe Farma Tbk PT Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kalbe Farma Tbk PT. The current cci is -85.67976954.

Kalbe Farma Tbk PT Daily Commodity Channel Index (CCI) ChartKalbe Farma Tbk PT Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kalbe Farma Tbk PT. The current cmo is -18.1589569.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Kalbe Farma Tbk PT Daily Chande Momentum Oscillator (CMO) ChartKalbe Farma Tbk PT Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kalbe Farma Tbk PT. The current willr is -76.66666667.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Kalbe is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Kalbe Farma Tbk PT Daily Williams %R ChartKalbe Farma Tbk PT Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Kalbe Farma Tbk PT.

Kalbe Farma Tbk PT Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kalbe Farma Tbk PT. The current atr is 42.26.

Kalbe Farma Tbk PT Daily Average True Range (ATR) ChartKalbe Farma Tbk PT Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kalbe Farma Tbk PT. The current obv is -1,067,976,388.

Kalbe Farma Tbk PT Daily On-Balance Volume (OBV) ChartKalbe Farma Tbk PT Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kalbe Farma Tbk PT. The current mfi is 35.93.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Kalbe Farma Tbk PT Daily Money Flow Index (MFI) ChartKalbe Farma Tbk PT Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kalbe Farma Tbk PT.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-01MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-02MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-28MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-26STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Kalbe Farma Tbk PT Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Kalbe Farma Tbk PT based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.067
Ma 20Greater thanMa 501,457.000
Ma 50Greater thanMa 1001,469.300
Ma 100Greater thanMa 2001,535.650
OpenGreater thanClose1,450.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Kalbe with someone you think should read this too:
  • Are you bullish or bearish on Kalbe? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kalbe? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kalbe Farma Tbk PT

I send you an email if I find something interesting about Kalbe Farma Tbk PT.


Comments

How you think about this?

Leave a comment

Stay informed about Kalbe Farma Tbk PT.

Receive notifications about Kalbe Farma Tbk PT in your mailbox!